BioSig CEO Kenneth L. Londoner to Present at the Benzinga Biotech Small Cap Conference
March 19 2021 - 12:15PM
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the
"Company"), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that it will present at the Benzinga
Biotech Small Cap Conference, being held virtually on March
24-25, 2021.
Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies,
Inc is scheduled to present on March 25th, 2021 at 12:20 PM
ET – track 2. During the presentation, Mr. Londoner will
provide an overview of the Company, including recent milestones for
its PURE EP™ System. Mr. Londoner will also be available for
one-on-one meetings.
BioSig’s PURE EP™ System is an advanced signal acquisition and
processing platform that seeks to set a new standard in
electrophysiology. The system provides essential diagnostic signals
with high clinical value in all types of cardiac ablations. More
than 40 physicians have completed over 600 patient cases with the
PURE EP™ System across 8 clinical sites.
For people interested in scheduling a one-on-one with
management, please use this link:
https://events.benzinga.com/order-form1614955808488
To register for the event, please use this link:
https://events.benzinga.com/registration-page16068526119171607978331877
Date and Time: March 25th, 2021 at 12:20 PM ET – track
2
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP™ System is a computerized
system intended for acquiring, digitizing, amplifying, filtering,
measuring and calculating, displaying, recording and storing of
electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024